Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
December 22, 2010BioTime, Inc. and the University of California System Sign Cell Transfer Agreement for Human Embryonic Stem Cell Lines
BioTime, Inc. (NYSE Amex: BTX) today announced a material transfer agreement (MTA) with the University of California (UC) system to make five research-grade human embryonic stem (hES) cell lines available to UC system researchers. These lines are genetically identical to a bank of GMP-compliant hES cell lines that will be made available to California-based researchers under a recent agreement between BioTime and the California Institute for Regenerative Medicine (CIRM). Institutions cove... 
Printer Friendly Version
December 09, 2010BioTime Asia, Limited and Shanghai Genext Medical Technology Co., Ltd. Sign Marketing Agreement for ACTCellerate™ Cell Lines
BioTime Asia, Limited, a subsidiary of BioTime, Inc. (NYSE Amex:BTX) today announced an agreement with Shanghai Genext Medical Technology Co., Ltd. to sell ACTCellerate™ cell lines to the medical and biological research communities in China, Taiwan, Hong Kong, and Macau. In addition to a wide array of human cell types, Genext will market cell culture media customized for each line. The marketing agreement includes provisions for an initial stocking inventory and annual milestones to main... 
Printer Friendly Version
December 03, 2010BioTime Plans Warrant Distribution to Shareholders
BioTime, Inc. (NYSE Amex: BTX) today announced that it plans to distribute new common share purchase warrants to the holders of BioTime common shares. Under the plan, shareholders will receive one warrant for every eight shares held. Each warrant will entitle the holder to purchase one common share for $12.00 per share. The warrants will expire four years after the date of issue. BioTime's Board of Directors has not yet set a record date for determining shareholders entitled to receive t... 
Printer Friendly Version
November 29, 2010BioTime, Inc. and the California Institute for Regenerative Medicine Sign Distribution Agreement for GMP-Compliant Human Embryonic Stem Cell Lines
BioTime, Inc. (NYSE Amex: BTX) today announced an agreement with the California Institute for Regenerative Medicine (CIRM) to make five clinical-grade human embryonic stem (hES) cell lines available to California-based researchers. CIRM is the stem cell agency created when California voters supported a $3 billion funding measure for stem cell-related research and clinical translation. Under the agreement, BioTime will initially provide research grade cell lines, and within one year, BioT... 
Printer Friendly Version
November 15, 2010BioTime Announces Third Quarter 2010 Financial Results and Recent Corporate Developments
82% Increase in Total Revenue Year-over-Year for the Quarter 92% Increase in Total Revenues Year to Date over Last Year BioTime, Inc. (NYSE Amex: BTX) today reported financial results for the quarter ended September 30, 2010 and provided an update on recent corporate developments. For the nine months ended September 30, 2010, total revenue (including royalty income, revenue recognition of deferred license fees, grant income, and sale of research products) was $2,261,375, up 92% from $... 
Printer Friendly Version
November 10, 2010BioTime's CEO Michael West to Present Keynote Address at BIT Life Sciences' 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010 in Shanghai, China
BioTime, Inc. (NYSE Amex: BTX) announced today that BioTime's CEO Dr. Michael West will present the keynote address at the BIT Life Sciences' 3rd Annual World Congress of Regenerative Medicine & Stem Cells 2010 in Shanghai, China on December 5, 2010. Dr. West's presentation will be titled "Regenerative Medicine: A Force for Change in Biotechnology." During his talk, Dr. West will present a group of new research products that the Company's subsidiary Embryome Sciences, Inc. ... 
Printer Friendly Version
November 04, 2010BioTime Announces Final Results of Warrant Exercises
BioTime, Inc. (NYSE Amex:BTX) today announced that in the last 18 months it has received cumulative total proceeds of $24,174,733 from exercises of warrants that expired November 1, 2010. A remaining 24,976 common share purchase warrants expired unexercised. BioTime now has approximately $32 million of cash on hand on a consolidated basis. BioTime plans to use the capital raised through the warrant exercises to strengthen its working capital reserves and for the expansion of its stem ce... 
Printer Friendly Version
November 03, 2010BioTime, Inc. Awarded $733,000 in Grants Under Qualifying Therapeutic Discovery Project Program
- Funding advances BioTime's therapeutic programs - ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTX) announced today that it has been awarded three grants totaling approximately $733,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program. The QTDP program was part of the Patient Protection and Affordable Care Act signed into law on March 23, 2010. The QTDP was created by Congress to support investment in qualified biomedical proje... 
Printer Friendly Version
October 26, 2010BioTime Expands Corporate Headquarters
- An Additional 6,000 Square Feet of Facilities for Therapeutic Product Development - ALAMEDA, Calif., Oct 26, 2010 (BUSINESS WIRE) --BioTime Inc. (NYSE Amex: BTIM) announced today it is expanding its corporate headquarters and laboratory facility in Alameda, California and has signed a new Lease Agreement effective December 1, 2010 for an initial five-year term, with an option to renew the lease for an additional five years. The new lease extends BioTi... 
Printer Friendly Version
October 22, 2010BioTime's CEO Michael West Presents 12 New ACTCellerateTM Cell Lines and New PureStemTM Products Slated for Launch in 2011 at GTCbio Stem Cell Conference Today
ALAMEDA, Calif., Oct 22, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced that the Company's CEO Dr. Michael West will present data today relating to 12 new cell lines, differentiation kits, and cell culture media at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West's presentation titled: "Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines" wi... 
Printer Friendly Version
October 14, 2010BioTime's CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010
ALAMEDA, Calif., Oct 14, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced today that on October 22, 2010 BioTime's CEO Dr. Michael West will present at the GTCbio 4th Advances in Stem Cell Discovery and Development Conference in San Francisco, California. Dr. West's presentation titled: "Fate Space Screening of Clonal Human ES-derived Embryonic Progenitor Cell Lines" will include a discussion of the Company's proprietary bank of more... 
Printer Friendly Version
October 12, 2010BioTime Announces Stock Ticker Symbol Change and Extension of Warrant Expiration Date
Trading Symbol for BioTime Common Shares to Change Effective November 2, 2010 BioTime Extends Expiration Date of Warrants to November 1, 2010 ALAMEDA, Calif., Oct 12, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM). BioTime announced today the change of its stock ticker symbol on the NYSE Amex. Additionally, BioTime announced today that it is extending the expiration date of its common share purchase warrants that expire on Octo... 
Printer Friendly Version
October 10, 2010Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.
To Develop and Market OpRegenTM for the Treatment of Age-Related Macular Degeneration JERUSALEM & ALAMEDA, Calif., Oct 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM), Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange:HDST) jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegenTM pr... 
Printer Friendly Version
October 10, 2010Cell Cure Neurosciences' Shareholders Will Invest $7.1 M in the Company's Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases
JERUSALEM & ALAMEDA, Calif., Oct 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM), Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange:HDST) jointly announced today that Cell Cure will receive an equity investment of $7.1 million from BioTime, Teva Pharmaceutical Industries Ltd., and Hadasit Bio-Holdings (HBL). This financial round extends previous investments by Teva and HBL in Cell Cure. BioTime already held a si... 
Printer Friendly Version
September 16, 2010BioTime CEO Dr. Michael West and CMO Dr. David Jin to Present Keynote Addresses at The Sixth Chinese Congress in Regenerative Medicine and Stem Cell Therapy in Suzhou, P.R. China
ALAMEDA, Calif., Sep 16, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced that Chief Executive Officer Michael West, Ph.D. will deliver a keynote presentation this week at the Sixth Chinese Congress in Regenerative Medicine and Stem Cell Therapy being held September 16-19, 2010 in Suzhou, P.R. China. This Congress is the largest of its type in China with over 2,000 participants from various stem cell-related disciplines. Dr. West's pre... 
Printer Friendly Version
September 13, 2010BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2010
Ten New ACTCellerate Cell Lines to be Launched October 1, 2010 ALAMEDA, Calif., Sep 13, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced that Chief Executive Officer Michael West, Ph.D. will give a presentation today at the Stem Cells USA & Regenerative Medicine Congress 2010 being held September 13-15, 2010 in Philadelphia, PA. Dr. West will give a presentation during a panel session discussing tools and technologies relating to manu... 
Printer Friendly Version
September 08, 2010BioTime Announces Executive Management Changes
ALAMEDA, Calif., Sep 08, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced today that its Chief Financial Officer, Steven A. Seinberg, has resigned his position effective September 17, 2010. Mr. Seinberg, who is an attorney, will be returning to the practice of law at a private firm. Mr. Seinberg has agreed to assist BioTime in transition tasks on a consulting basis. Mr. Seinberg has reported to BioTime's Senior Vice President and Chief ... 
Printer Friendly Version
August 26, 2010BioTime to Launch Seven New Embryonic Progenitor Cell Lines on September 1, 2010
ALAMEDA, Calif., Aug 26, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that it will launch seven new human embryonic progenitor cell lines and seven novel culture media for these lines on September 1, 2010. These progenitor lines were produced from embryonic stem cells using the Company's ACTCellerateTM technology. Human embryonic progenitor cells are intermediate in the developmental process between embryonic stem cells and f... 
Printer Friendly Version
August 19, 2010BioTime Raises $9.2 Million in Warrant Discount Offer
ALAMEDA, Calif., Aug 19, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced the completion of its warrant discount offer which closed at 5:00 p.m., New York time, on August 18, 2010. The deadline for submitting warrant certificates and exercise funds under notices for guaranteed delivery is August 23, 2010 at 5:00 p.m., New York time. Based upon preliminary results, the warrant discount offer generated $9,195,422 of proceeds to BioTime fr... 
Printer Friendly Version
August 16, 2010BioTime Announces Second Quarter 2010 Financial Results and Recent Corporate Developments
57% Increase in Total Revenue for the Quarter 99% Increase in Total Revenues Year to Date over Last Year ALAMEDA, Calif., Aug 16, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) today reported financial results for the quarter ended June 30, 2010 and provided an update on recent corporate developments. For the three months ended June 30, 2010, total revenue (including royalty income, revenue recognition of deferred license fees, and grant income) wa... 
Printer Friendly Version
July 21, 2010BioTime Announces Addition of New Stem Cell Lines to Its Product Portfolio
ALAMEDA, Calif., Jul 21, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX:BTIM) announced today that on August 1, 2010 the Company will be offering for sale 21 new stem cell products for research use only. These products will include the novel stem cell lines: E120 expressing the gene LGR5 useful in colon cancer drug discovery, EN16, T43, RAD20.5, RA-SKEL8, SM22, and Z1, full properties of which will be disclosed on product launch, along with differentiation kit... 
Printer Friendly Version
July 19, 2010BioTime, Inc. Provides Financial Information about Its Acquisition of ES Cell International Pte Ltd.
ALAMEDA, Calif., Jul 19, 2010 (BUSINESS WIRE) --On Friday, July 16, 2010 BioTime, Inc. (NYSE Amex: BTIM) filed an amendment to its Current Report on Form 8-K with the Securities and Exchange Commission reporting BioTime's acquisition of ES Cell International Pte Ltd, a Singapore private limited company ("ESI"). BioTime filed the amendment in the time frame provided in the SEC's rules to include audited financial statements of ESI and pro forma fina... 
Printer Friendly Version
July 09, 2010BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2010
ALAMEDA, Calif., Jul 09, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) Chief Executive Officer Michael West, Ph.D., will give a presentation at the Agora Financial Investment Symposium 2010, July 20-23, at the Fairmont Hotel Vancouver. Dr. West's presentation on Wednesday, July 21, is titled "Regenerative Medicine: Finding Opportunity in a Scientific Revolution." The Symposium is the 11th for Agora Financial, LLC, an independent firm p... 
Printer Friendly Version
July 06, 2010BioTime Announces Passing of Board Director Dr. Robert N. Butler
ALAMEDA, Calif., Jul 06, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced with sadness that Dr. Robert N. Butler, a member of its Board of Directors, passed away on Sunday, July 4, 2010 at the age of 83. Dr. Butler was a leading expert in geriatrics and diseases associated with the aging process, and founded the International Longevity Center-USA, a non-profit international research, policy, and education organization formed to educate ... 
Printer Friendly Version
June 18, 2010BioTime Commences Warrant Discount Offer
ALAMEDA, Calif., Jun 18, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share. The discount offer will expire at 5:00 p.m., New Y... 
Printer Friendly Version
June 14, 2010BioTime Announces Results of Vote at Annual Shareholders Meeting
Annual Meeting Presentation Now Available on BioTime's Website ALAMEDA, Calif., Jun 14, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that all of the nominees for election to the BioTime Board of Directors were re-elected by BioTime's shareholders at the 2010 Annual Meeting held on June 10. Each nominee received not less than 99.8% of the votes cast at the meeting. Our directors are Neal C. Bradsher, Arnold I. Burns, Robert N. Butler, ... 
Printer Friendly Version
June 13, 2010BioTime Set to Join Russell 3000 Index
ALAMEDA, Calif., Jun 13, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM) announced today that it has been included on a preliminary list of additions to the Russell 3000(R) Index and Russell Global(R) Index posted by Russell Investments on June 11, 2010 at www.russell.com. These changes are expected to go into effect after the close of trading on Friday, June 25, 2010 and remain in place for one year. BioTime expects that inclusion in the Russell 300... 
Printer Friendly Version
June 10, 2010BioTime Forms New Subsidiary, OrthoCyte Corporation, to Develop Treatments for Orthopedic Conditions Using Stem Cell Technology
Arnold I. Caplan Ph.D., Founder of Osiris Therapeutics, Inc. Appointed Chief Scientific Officer ALAMEDA, Calif., Jun 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced today that it has organized a new subsidiary, OrthoCyte Corporation, for the purpose of developing novel therapeutics based on stem cell technology for the treatment of injuries and disorders affecting the musculoskeletal system, including therapeutics that would regener... 
Printer Friendly Version
June 08, 2010BioTime CEO Dr. Michael West to Present at the Inaugural Jefferies Global Life Sciences Conference
ALAMEDA, Calif., Jun 08, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX: BTIM) Chief Executive Officer Michael West, Ph.D., will give a presentation this week at the Inaugural Jefferies Global Life Sciences Conference being held June 8-11, 2010 in New York City. Dr. West will give an overview of BioTime's business and technology in the stem cell and regenerative medicine sector on Wednesday, June 9 at 11:00 a.m. EDT, Track C. The presentation will be webcast l... 
Printer Friendly Version
May 27, 2010BioTime Adds Five New Stem Cell Lines to Its Product Portfolio
ALAMEDA, Calif., May 27, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX:BTIM) announced today that on June 1, 2010 the Company will be offering for sale five new human stem cell lines for research use only. These cell lines were developed using BioTime's ACTCellerate(TM) technology. These highly purified, novel, and scalable cell lines are embryonic progenitors, meaning that they are intermediate between human embryonic stem cells and fully developed cells. Th... 
Printer Friendly Version
May 21, 2010BioTime CEO Dr. Michael West to Present at GTCbio 6th Annual Stem Cell Research & Therapeutics Conference
ALAMEDA, Calif., May 21, 2010 (BUSINESS WIRE) --BioTime, Inc. (AMEX:BTIM) Chief Executive Officer Michael West, Ph.D. will give a presentation next week at the GTCbio 6th Annual Stem Cell Research & Therapeutics Conference, which will be held May 27-28, 2010 in Boston, Massachusetts. Dr. West will speak on "Fate Space Screening of Clonal Human ES-Derived Embryonic Progenitor Cell Lines for Chondrogenesis" in the meeting's first session, whose t... 
Printer Friendly Version
May 10, 2010BioTime Announces Receipt of $8 Million from Early Exercise of Warrants
Proceeds to Accelerate Pace of Stem Cell Product Development Company to Offer Same Early Exercise Terms to Other Warrant Holders ALAMEDA, Calif., May 10, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM), a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has received an additional $8 million from two investors. These two investors have elected to exercise early an... 
Printer Friendly Version
May 05, 2010BioTime Announces First Quarter 2010 Financial Results and Recent Corporate Developments
159% Increase in Total Revenue for the Quarter ALAMEDA, Calif., May 05, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments. For the three months ended March 31, 2010, total quarterly revenue (including royalty income, revenue recognition of deferred license fees, and grant income) was $767,127, up 159% from $296,743 for the ... 
Printer Friendly Version
May 03, 2010BioTime, Inc. Announces Completion of ES Cell International Pte Ltd Acquisition
Acquisition to Accelerate Development of Research and Therapeutic Products ALAMEDA, Calif., May 03, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM), a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd ("ESI"). Established in 2000, ESI has been a worldwide leader in the deve... 
Printer Friendly Version
April 29, 2010BioTime, Inc. Provides Additional Information on Acquisition of Promissory Notes in Connection with Planned Acquisition of ES Cell International Pte Ltd.
ALAMEDA, Calif., Apr 29, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex: BTIM) announced earlier today that it plans to acquire ES Cell International Pte Ltd, a Singapore private limited company ("ESI"). In its press release earlier today, BioTime stated that it will "acquire all of ESI's approximately $35 million of debt and accrued interest. ESI has no significant liabilities other than the debt obligations that BioTime will own after the acquisition." ... 
Printer Friendly Version
April 29, 2010BioTime, Inc. Announces Agreement to Acquire ES Cell International
Acquisition to Accelerate BioTime's Development of Human Stem Cell-Based Therapeutics ALAMEDA, Calif., Apr 29, 2010 (BUSINESS WIRE) --BioTime, Inc. (NYSE Amex:BTIM), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd (ESI). The acquisition is expected to close next week, at which time BioTi... 
Printer Friendly Version
March 16, 2010BioTime, Inc. Reports Peer-Reviewed Scientific Publication on the Reversal of the Developmental Aging of Normal Human Cells
Paper and Related Patent Filings Are a Strategic Step Forward in the Development of the Company's ReCyte(TM) iPS TechnologyALAMEDA, Calif., Mar 16, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM), a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled "Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcription... 
Printer Friendly Version
March 10, 2010BioTime Announces Fourth Quarter and Fiscal Year-End 2009 Financial Results and Recent Corporate Developments
163% Increase in Total Revenue for the Quarter28% Increase in Total 2009 RevenueALAMEDA, Calif., Mar 10, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM) today reported financial results for the fourth quarter and fiscal year ended December 31, 2009 and provided an update on recent corporate developments. For the three months ended December 31, 2009 total quarterly revenue (including royalty income, revenue recognition of deferred license fees, and grant in... 
Printer Friendly Version
February 05, 2010BioTime Reports Results from Independent Hextend(R) Study
-- First Report on Hextend for Initial Fluid Resuscitation at a Level I Trauma Center --ALAMEDA, Calif., Feb 05, 2010 (BUSINESS WIRE) -- BioTime, Inc. (NYSE Amex:BTIM) today reported recently-released results from an independent study evaluating the use of Hextend(R) in hemodynamically unstable trauma patients. Hextend (6% Hetastarch in Lactated Electrolyte Injection) is BioTime's commercially-available blood plasma volume expander used to treat hypovolemia (low b... 
Printer Friendly Version
January 05, 2010BioTime Commences Shipment of Stem Cell Research Products to Millipore
BioTime, Inc. (NYSE Amex:BTIM) announced today that it has initiated shipments of stem cell research products to its worldwide distributor, Millipore Corporation, according to the terms of the co-marketing agreement between the two companies that was announced on July 9, 2009. BioTime has shipped inventory of six ACTCellerate™ progenitor cell lines to Millipore and plans to begin shipments of additional cell lines and ESpan™ cell growth media in the next several weeks. Derived from human... 
Printer Friendly Version